“The problem facing our biomedical industry has been that most vaccine and drug candidates needed to be sent overseas to be produced in large quantities for clinical trials, adding burdensome costs that have crushed many Australian businesses and researchers as the invention languishes on the lab bench," saod CSIRO chief executive Dr Larry Marshall.
CSIRO opens 'missing link' lab to develop Australian vaccine pipeline
August 12, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
NDIS keeps growing but signs emerge that reforms are starting to work
July 17, 2025 - - Latest News -
USTR launches new investigation, with minimal ambition on pharmaceuticals
July 17, 2025 - - Latest News -
New Zealand starting to benefit after lifting advertising prohibition
July 17, 2025 - - Latest News -
Mark Butler restates support for health technology assessment reform
July 16, 2025 - - Latest News -
Brandon BioCatalyst welcomes the inclusion of its CUREator in new program
July 16, 2025 - - Australian Biotech -
Cancer Australia launches research program targeting early-onset cancers
July 16, 2025 - - Latest News -
Imugene completes significant placement and launches share purchase plan
July 16, 2025 - - Australian Biotech